FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059249474> ?p ?o ?g. }

• W2059249474 endingPage "214" @default.
• W2059249474 startingPage "206" @default.
• W2059249474 abstract "Extended-release guanfacine (GXR) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness.Data from two large double-blind placebo-controlled pivotal trials of GXR in the treatment of ADHD were analyzed. Using the pooled population to provide sufficient sample size and associated statistical power, the impact of GXR treatment on core ADHD symptoms was examined by comparing ADHD Rating Scale IV (ADHD-RS-IV) total scores in the overall GXR and placebo groups in subjects with each of the three ADHD subtypes. ADHD-RS-IV Hyperactivity-Impulsivity and Inattentiveness subscale scores in the overall study population by randomized dose group (vs. placebo) were also examined.The full analysis set included 631 subjects aged 6-17 years (GXR: n=490; placebo: n=141). Among subjects with the predominantly inattentive subtype of ADHD, differences in least squares (LS) mean reductions from baseline in ADHD-RS-IV total scores were significantly greater in GXR-treated subjects (n=127) than in placebo-treated subjects (n=38) at treatment weeks 3 through 5 and end point (p≤0.020). Among subjects with combined type ADHD, differences in LS mean ADHD-RS-IV total score reductions from baseline were significantly greater in the GXR group (n=354) than in the placebo group (n=100) at treatment weeks 1 through 5 and end point (p≤0.011). The dearth of predominantly hyperactive-impulsive type subjects (n=12) precluded analysis of this subgroup. Each randomized GXR dose group in each trial demonstrated significantly greater reductions from baseline in ADHD-RS-IV Hyperactivity-Impulsivity and Inattentiveness subscale scores than did the respective placebo group at end point (p≤0.05 for all).The results support the use of GXR in the treatment of core ADHD symptoms as defined in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision, including hyperactivity, impulsivity, and inattention." @default.
• W2059249474 created "2016-06-24" @default.
• W2059249474 creator A5018605669 @default.
• W2059249474 creator A5024486752 @default.
• W2059249474 creator A5068191739 @default.
• W2059249474 date "2012-06-01" @default.
• W2059249474 modified "2023-09-26" @default.
• W2059249474 title "Efficacy of Guanfacine Extended Release in the Treatment of Combined and Inattentive Only Subtypes of Attention-Deficit/Hyperactivity Disorder" @default.
• W2059249474 cites W1971098431 @default.
• W2059249474 cites W1996216844 @default.
• W2059249474 cites W1999789853 @default.
• W2059249474 cites W2002134787 @default.
• W2059249474 cites W2016477915 @default.
• W2059249474 cites W2017449681 @default.
• W2059249474 cites W2022741651 @default.
• W2059249474 cites W2048892255 @default.
• W2059249474 cites W2082364777 @default.
• W2059249474 cites W2110145837 @default.
• W2059249474 cites W2111662787 @default.
• W2059249474 cites W2144269887 @default.
• W2059249474 cites W2150738535 @default.
• W2059249474 cites W2164549762 @default.
• W2059249474 cites W2171074660 @default.
• W2059249474 cites W4235816496 @default.
• W2059249474 cites W4248505544 @default.
• W2059249474 doi "https://doi.org/10.1089/cap.2010.0135" @default.
• W2059249474 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3373219" @default.
• W2059249474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22612526" @default.
• W2059249474 hasPublicationYear "2012" @default.
• W2059249474 type Work @default.
• W2059249474 sameAs 2059249474 @default.
• W2059249474 citedByCount "26" @default.
• W2059249474 countsByYear W20592494742012 @default.
• W2059249474 countsByYear W20592494742013 @default.
• W2059249474 countsByYear W20592494742014 @default.
• W2059249474 countsByYear W20592494742015 @default.
• W2059249474 countsByYear W20592494742016 @default.
• W2059249474 countsByYear W20592494742018 @default.
• W2059249474 countsByYear W20592494742019 @default.
• W2059249474 countsByYear W20592494742020 @default.
• W2059249474 countsByYear W20592494742021 @default.
• W2059249474 countsByYear W20592494742022 @default.
• W2059249474 countsByYear W20592494742023 @default.
• W2059249474 crossrefType "journal-article" @default.
• W2059249474 hasAuthorship W2059249474A5018605669 @default.
• W2059249474 hasAuthorship W2059249474A5024486752 @default.
• W2059249474 hasAuthorship W2059249474A5068191739 @default.
• W2059249474 hasBestOaLocation W20592494742 @default.
• W2059249474 hasConcept C118552586 @default.
• W2059249474 hasConcept C126322002 @default.
• W2059249474 hasConcept C142724271 @default.
• W2059249474 hasConcept C15744967 @default.
• W2059249474 hasConcept C168563851 @default.
• W2059249474 hasConcept C204787440 @default.
• W2059249474 hasConcept C27081682 @default.
• W2059249474 hasConcept C2778399450 @default.
• W2059249474 hasConcept C2780319597 @default.
• W2059249474 hasConcept C2780783007 @default.
• W2059249474 hasConcept C2780815205 @default.
• W2059249474 hasConcept C2908647359 @default.
• W2059249474 hasConcept C3017694942 @default.
• W2059249474 hasConcept C71924100 @default.
• W2059249474 hasConcept C99454951 @default.
• W2059249474 hasConceptScore W2059249474C118552586 @default.
• W2059249474 hasConceptScore W2059249474C126322002 @default.
• W2059249474 hasConceptScore W2059249474C142724271 @default.
• W2059249474 hasConceptScore W2059249474C15744967 @default.
• W2059249474 hasConceptScore W2059249474C168563851 @default.
• W2059249474 hasConceptScore W2059249474C204787440 @default.
• W2059249474 hasConceptScore W2059249474C27081682 @default.
• W2059249474 hasConceptScore W2059249474C2778399450 @default.
• W2059249474 hasConceptScore W2059249474C2780319597 @default.
• W2059249474 hasConceptScore W2059249474C2780783007 @default.
• W2059249474 hasConceptScore W2059249474C2780815205 @default.
• W2059249474 hasConceptScore W2059249474C2908647359 @default.
• W2059249474 hasConceptScore W2059249474C3017694942 @default.
• W2059249474 hasConceptScore W2059249474C71924100 @default.
• W2059249474 hasConceptScore W2059249474C99454951 @default.
• W2059249474 hasIssue "3" @default.
• W2059249474 hasLocation W20592494741 @default.
• W2059249474 hasLocation W20592494742 @default.
• W2059249474 hasLocation W20592494743 @default.
• W2059249474 hasLocation W20592494744 @default.
• W2059249474 hasOpenAccess W2059249474 @default.
• W2059249474 hasPrimaryLocation W20592494741 @default.
• W2059249474 hasRelatedWork W1987953300 @default.
• W2059249474 hasRelatedWork W2059249474 @default.
• W2059249474 hasRelatedWork W2157295589 @default.
• W2059249474 hasRelatedWork W2229759830 @default.
• W2059249474 hasRelatedWork W2312385617 @default.
• W2059249474 hasRelatedWork W2535658575 @default.
• W2059249474 hasRelatedWork W3004715821 @default.
• W2059249474 hasRelatedWork W3012495376 @default.
• W2059249474 hasRelatedWork W4377288895 @default.
• W2059249474 hasRelatedWork W594889888 @default.
• W2059249474 hasVolume "22" @default.
• W2059249474 isParatext "false" @default.
• W2059249474 isRetracted "false" @default.

• next